Exelixis
EXEL
#1647
Rank
โ‚น1.271 T
Marketcap
โ‚น5,059
Share price
-5.25%
Change (1 day)
55.61%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): โ‚น280.56

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น298.57. In 2025 the company made an earnings per share (EPS) of โ‚น275.68.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น280.561.77%
2025โ‚น275.68
2023โ‚น62.3214.61%
2022โ‚น54.37-22.97%
2021โ‚น70.59100%
2020โ‚น35.29-65.09%
2019โ‚น101.11-53.91%
2018โ‚น219.40333.96%
2017โ‚น50.56-260.61%
2016-โ‚น31.48-58.75%
2015-โ‚น76.31-42.45%
2014-โ‚น132.595.3%
2013-โ‚น125.91

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น833.20 179.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น124.96-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,381 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น244.17-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น341.01 14.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น339.59 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น370.72 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น2,270-860.38%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น80.13-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA